ReviewFrontiers in microbiology2020
Epidemiological Characteristics and Formation Mechanisms of Multidrug-Resistant Hypervirulent
Review in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.
- Pooled it
- A 6His-2Flag dual-tag strategy enables high-yield production of antimicrobial peptide N6 inSynthetic and systems biotechnology · 2027Article
- Article
- Distribution of mrk genes among uopathogenic Klebsiella pneumoniae.Journal of applied genetics · 2026Article
- Carbapenem-Resistant Enterobacterales (CRE) in Europe: Surveillance Challenges, Emerging Threats and Public Health Preparedness.Antibiotics (Basel, Switzerland) · 2026Review
- Biofilm-Mediated Antimicrobial Resistance in PediatricAntibiotics (Basel, Switzerland) · 2026Review
- Distinct and shared impacts of virulence plasmids on the phenotype and transcriptome in convergent carbapenem-resistant and hypervirulentMicrobiology spectrum · 2026Article
- Genome editing of phylogenetically distinct bacteria using cross-species retron-mediated recombineering.Nature biotechnology · 2026Article
- Genomic Insights into Antimicrobial Resistance and Plasmid-Mediated Dissemination inAntibiotics (Basel, Switzerland) · 2026Article
- Differential contributions of ClpX and ClpP to pulmonary virulence in classical and hypervirulentInfection and immunity · 2026Article
- <p>Molecular medicine reports · 2026Review
- Genomic and Clinical Profile of HypervirulentPathogens (Basel, Switzerland) · 2026Article
- Carriage of hypervirulent and ESBL-producingApplied and environmental microbiology · 2026Article
- Biological characterization and genomic analysis of Kpp-61, a lytic bacteriophage against K1-type Klebsiella pneumoniae.Archives of virology · 2026Article
- Coexistence of carbapenemase and hypervirulence-associated genes amongFrontiers in microbiology · 2026Article
- A rapid detection system for core virulence and resistance genes in hypervirulentFrontiers in microbiology · 2026Article
- Carbapenem-resistant hypervirulentFrontiers in microbiology · 2026Review
- Hybrid plasmids: genetic diversity and hypervirulent phenotype ofFrontiers in microbiology · 2026Article
- Glycoconjugate Vaccines Against Nosocomial Klebsiella pneumoniae Infections.Advances in experimental medicine and biology · 2026Article
- Emergence and genomic characterization of hypervirulent ST23/K1Frontiers in microbiology · 2026Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multi-drug resistance (MDR) and hypervirulence (hv) were exhibited by different well-separated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.